Basisstatistiken
| LEI | 529900ZIDI5C9C9TTI91 |
| CIK | 1660046 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immuron Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 28, 2026 |
Exhibit 99.1 28 May 2026 Ms Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) ASX Limited Dear Ms Kostopoulos RE: Immuron Limited (‘IMC’): Response to Price Query I refer to your letter dated 28 May 2026 regarding IMC’s Price Query. The Company’s responses to the numbered questions set out in the letter are as follows: 1. Is IMC aware of any information concerning it that has not |
|
| May 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 8, 2026 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, May 8 , 2026 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Thursday 7 th May 2026 ( 10 : 15 am - 10 : 45 am U . S . Eastern Time) . A copy of the presentation made is i |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 30, 2026 |
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, April 30, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Thursday 7th May 2026 (10:15am - 10:45am U.S. Eastern Time). Please submit your questions in advance to Que |
|
| April 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 17, 2026 |
Immuron Double Digit 3Q Sales Growth Exhibit 99.1 ASX/NASDAQ Announcement Immuron Double Digit 3Q Sales Growth Sales Highlights (unaudited): Global ● Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp) ● YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp) Australia ● Q3 sales AUD$0.9 million up 15% on prior comparative period (pcp) ● YTD Mar 2026 sales AUD$4.2 million up 14% on prior comparative p |
|
| April 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 13, 2026 |
Small Holding Share Sale Facility Exhibit 99.1 ASX Announcement 13 April 2026 Small Holding Share Sale Facility Immuron Limited (ASX:IMC and NASDAQ: IMRN) (Immuron or the Company) is pleased to announce that it is providing eligible holders of small parcels of ordinary shares the opportunity to sell their shareholding without incurring brokerage or handling costs. To facilitate this, the Company has established a Small Holding Sha |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 5, 2026 |
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference Melbourne, Australia, March 5, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time). A copy of the presentation made is in |
|
| March 2, 2026 |
Exhibit 99.2 25 February 2026 Steven Lydeamore Chief Executive Officer Strategic Reset and HY26 Results NASDAQ: IMRN ASX: IMC Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| March 2, 2026 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2025 Previous period: For the period ended 31 December 2024 2. Results for announcement to the market $ Revenue from ordinary activities up 4.8 % 4,184,357 Loss from ordinary activities after tax attributable to the memb |
|
| February 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 17, 2026 |
Immuron receives R&D Tax Incentive Exhibit 99.1 ASX Announcement Immuron receives R&D Tax Incentive Melbourne, Australia, February 17, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise that it has received its R&D Tax Incentive of A$1,121,885 for eligible activities conducted during financial year ending June 30, 2025. The Australian Government’s Research and Development Tax Incentive is a program to encourage bus |
|
| February 12, 2026 |
2026 Extraordinary General Meeting Results Exhibit 99.1 ASX/NASDAQ Announcement 12 February 2026 2026 Extraordinary General Meeting Results In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2026 Extraordinary General Meeting held earlier today. Al |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 9, 2026 |
Resignation/Appointment of Company Secretary and Chief Financial Officer Exhibit 99.1 ASX Announcement 9 February 2026 Resignation/Appointment of Company Secretary and Chief Financial Officer Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises, in accordance with ASX Listing Rule 3.16.1, that Mr Phillip Hains has resigned as Chief Financial Officer and Company Secretary, effective 9 February 2026. The Board thanks Mr Hains for his valuable contribution to the Company sinc |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 23, 2026 |
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, January 23, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Thursday 22nd January 2026 (2:40pm - 2:50pm U.S. Eastern Time). A copy of the presentation made is included b |
|
| January 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 20, 2026 |
Immuron Continued Sales Growth Exhibit 99.1 ASX Announcement Immuron Continued Sales Growth Sales Highlights (unaudited): Global ● H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) ● Q2 sales AUD$2.2 million up 11% on prior quarter Australia ● H1 sales AUD$3.3 million up 13% on prior comparative period (pcp) ● Q2 sales AUD$1.7 million up 11% on prior quarter ● Australian launch of ProIBS® Canada ● H1 sales AUD$56 |
|
| January 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 14, 2026 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, January 14, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Thursday 22nd January 2026 (2:40pm - 2:50pm U.S. Eastern Time). Please register to ensure you are able |
|
| January 12, 2026 |
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF EXTRAORDINARY GENERAL MEETING AND EXPLANATORY STATEMENT Date and Time of Meeting: Thursday, 12 February 2026 at 11.00 am AEDT Place of Meeting: Level 3, 62 Lygon Street, Carlton VIC 3053 If Shareholders are unable to attend the Meeting in person they are encouraged to return the proxy form to the Company in a |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2026 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 16, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, December 16, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 16 December 2025 Number Issued 314,843 The Company gives notice under section 708A(5)(e) of the |
|
| December 16, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Tuesday December 16, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securitie |
|
| December 15, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, December 15, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 15 December 2025 Number Issued 1,142,909 The Company gives notice under section 708A(5)(e) of t |
|
| December 15, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Monday December 15, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities |
|
| December 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 12, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday December 11, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securiti |
|
| December 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 12, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, December 11, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 11 December 2025 Number Issued 1,874,964 The Company gives notice under section 708A(5)(e) of t |
|
| December 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 10, 2025 |
Uniformed Services University to Release Topline Data Exhibit 99.1 Uniformed Services University to Release Topline Data Highlights: ● Primary Endpoint did not reach statistical significance ● Investigational product was manufactured by a third party and was not administered in accordance with Travelan® directions for use ● Immuron will propose the established and clinically validated three times daily dosing schedule at an End-of-Phase 2 meeting wit |
|
| December 5, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday December 05, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +secur |
|
| December 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 4, 2025 |
CHANGE OF PROVIDER OF SHARE REGISTRY MANAGEMENT SERVICES FOR IMMURON LIMITED Exhibit 99.1 ASX Announcement 4 December 2025 CHANGE OF PROVIDER OF SHARE REGISTRY MANAGEMENT SERVICES FOR IMMURON LIMITED In accordance with listing rule 3.15.1, Immuron Limited (ASX: IMC, NASDAQ: IMRN or the Company) advises that as of Monday, 8 December 2025, the company will change the registry management services from Automic Group to Boardroom Pty Limited: Boardroom’s contact details are as |
|
| December 4, 2025 |
Appendix 3B - Proposed issue of securities Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 4/12/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be |
|
| December 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| December 3, 2025 |
Immuron New U.S. Department of Defense Award & Clinical Trial Update Exhibit 99.1 Immuron New U.S. Department of Defense Award & Clinical Trial Update Highlights: ● New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella ● Uniformed Services University P2TD clinical study update Melbourne, Australia, December 3, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmac |
|
| December 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 21, 2025 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.1 Confidential Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Immuron Limited ABN 80 063 114 045 We (t |
|
| November 12, 2025 |
2025 Annual General Meeting Results Exhibit 99.2 ASX/NASDAQ Announcement 11 November 2025 2025 Annual General Meeting Results In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2025 Annual General Meeting held earlier today. All resolutions |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 12, 2025 |
2025 Annual General Meeting - CEO Address Exhibit 99.1 ASX/NASDAQ Announcement 11 November 2025 2025 Annual General Meeting - CEO Address Immuron Limited (ASX: IMC; NASDAQ: IMRN) attaches the CEO Address to be delivered by Chief Executive Officer, Steve Lydeamore, at this morning’s Annual General Meeting. - - - END - - - This release has been authorised by the Directors of Immuron Limited. Further information Steven Lydeamore Chief Execut |
|
| November 7, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday November 07, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +secur |
|
| November 7, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, November 7, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 7 November 2025 Number Issued 8,495,080 The Company gives notice under section 708A(5)(e) of the |
|
| November 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 6, 2025 |
Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 6/11/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 5, 2025 |
Immuron IMM-529 IND approved by FDA Exhibit 99.1 Immuron IMM-529 IND approved by FDA Key Points ● Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceed ● FDA assigned an IND number (032095) for the IMM-529 application ● IND 32095 is Immuron’s Investigational new drug (IND) application for clinical development of IMM-529 as product to sp |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| October 31, 2025 |
Immuron Announces Clinical Trial Update Exhibit 99.1 Immuron Announces Clinical Trial Update ● IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted ● Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown Melbourne, Australia, October 31, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), a |
|
| October 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 27, 2025 |
Appendix 3H - Notification of cessation of securities Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Monday October 27, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities to that have ceased The +securities have ceased due to Date of cessation IMCAI OPTION EXPIRING VA |
|
| October 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 24, 2025 |
Immuron launch PROIBS® for Irritable Bowel Syndrome (IBS) Exhibit 99.1 Immuron launch PROIBS® for Irritable Bowel Syndrome (IBS) Melbourne, Australia, October 24, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the official launch of PROIBS® into the Australian market. Immuron has already received pharmacy orders for the innovative product that treats the symptom |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 23, 2025 |
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, October 23, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Wednesday 22nd October 2025 (4:10pm - 4:20pm U.S. Eastern Time). A copy of the presentation being ma |
|
| October 21, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, October 20, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 20 October 2025 Number Issued 1,133,840 The Company gives notice under section 708A(5)(e) of the |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 21, 2025 |
Immuron CEO, Steven Lydeamore presentation to AusBiotech Invest 2025 conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to AusBiotech Invest 2025 conference Melbourne, Australia, October 21, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the AusBiotech Invest conference on Tuesday 21st October 2025 (4:00 pm Australian Eastern time) in Melbourne. A copy of the presentation |
|
| October 21, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Monday October 20, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 20, 2025 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, October 20, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Wednesday 22nd October 2025 (4:10pm - 4:20pm U.S. Eastern Time). Mr. Steven Lydeamore, Chief Executive |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 17, 2025 |
Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 17/10/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code +Security description Maximum Number of +securities to be |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 14, 2025 |
Exhibit 99.1 ASX Announcement 13 October 2025 Immuron Q1 FY26 YoY growth Sales Highlights (unaudited): Global ● Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia ● Q1 sales AUD$1.6 million up 52% on pcp Canada ● Q1 sales AUD$0.0 million down 92% on pcp USA ● Q1 sales AUD$0.4 million up 44% on pcp Melbourne, Australia, October 13, 2025: Immuron Limited (ASX: IMC; NASDAQ: I |
|
| October 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 10, 2025 |
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2025 ANNUAL GENERAL MEETING AND EXPLANATORY STATEMENT Date and Time of Meeting: Tuesday, 11 November 2025 at 11.15 am AEDT Place of Meeting: The Offices of Grant Thornton Collins Square, Tower 5 Level 22, 727 Collins Street Melbourne VIC 3008 If Shareholders are unable to attend the Meeting in person they are |
|
| October 8, 2025 |
Immuron Submits IMM-529 IND to FDA Exhibit 99.1 Immuron Submits IMM-529 IND to FDA Key Points ● Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) ● Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Melbourne, Australia, October 8, 2025: Immuron Limited ( |
|
| October 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 3, 2025 |
IMMRUON LIMITED Up to $2,847,954 American Depositary Shares Representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-280667 PROSPECTUS SUPPLEMENT (To Prospectus dated July 19, 2024) IMMRUON LIMITED Up to $2,847,954 American Depositary Shares Representing Ordinary Shares This prospectus supplement amends, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our Offering Agreement prospectus dated July 19, |
|
| October 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 2, 2025 |
Exhibit 99.1 October 2, 2025 ASX/Nasdaq Announcement Letter to Shareholders Highlights: ● US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical products ● Travelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 ● IMM-529 Regulatory Milestone: |
|
| October 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 26, 2025 |
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Exhibit 99.1 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Immuron Limited ABN/ARBN Financial year ended: 80 063 114 045 30 June 2025 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: ☒ This URL on our website: www.immuron.com.au/corporate-directory-and-go |
|
| September 25, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philip Hains, Chief Financial Officer of the Company, cer |
|
| September 25, 2025 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Steven Lydeamore, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| September 25, 2025 |
This version approved by the Board on 09 Sept 2022. Exhibit 11.1 Immuron limited (ASX: IMC) Corporate Governance Charters and Policies 2022 This version approved by the Board on 09 Sept 2022. www.immuron.com.au Contents 1 INTRODUCTION 3 CHARTERS 5 2 BOARD CHARTER 5 3 AUDIT AND RISK COMMITTEE CHARTER 13 4 REMUNERATION and NOMINATION COMMITTEE CHARTER 17 POLICIES 20 5 ANTI-BRIBERY AND ANTI-CORRUPTION POLICY 20 6 CODE OF CONDUCT 25 7 COMMUNICATION AND |
|
| September 25, 2025 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Philip Hains, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| September 25, 2025 |
Volume Invoiced per Commercial Year Exhibit 4.9 Manufacture and supply agreement Consolidating all agreed amendments as at 1 April 2025 to the original agreement signed 6 April 2018 Mayne Pharma International Pty Ltd (Mayne Pharma) Immuron Ltd (Customer) Table of contents Table of contents 2 Details 5 Agreed terms 5 1. Defined terms & interpretation 5 1.1 Defined terms 5 1.2 Interpretation 8 1.3 Inconsistency 9 2. Supply and Purchas |
|
| September 25, 2025 |
Exhibit 4.7 Employment Agreement This employment agreement is made on October 2023 between Immuron Limited ACN 063 114 045 of Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia (Employer) and Flavio Palumbo (Employee). BACKGROUND A. The Employer initiated revision of the existing Employment agreement to revise terms and conditions in line with changes in laws and regulations and E |
|
| September 25, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Lydeamore, Chief Executive Officer of the Company, |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 16, 2025 |
Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia, September 16, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Coffee Microcaps VIP Conference on Tuesday 16th September 2025 (9.45am Australian Eastern time) in Sydney. A copy of the presentation bei |
|
| September 2, 2025 |
Exhibit 99.2 |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 2, 2025 |
Exhibit 99.1 Immuron Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the year ended 30 June 2025 Previous period: For the year ended 30 June 2024 2. Results for announcement to the market $ Revenue from ordinary activities up 48.6% to 7,287,002 Loss from ordinary activities after tax attributable to the membe |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 26, 2025 |
Immuron partners with InvestorHub Exhibit 99.2 Immuron partners with InvestorHub Melbourne, Australia, August 26, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to bett |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 15, 2025 |
Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Exhibit 99.2 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Friday August 15, 2025 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issued |
|
| August 13, 2025 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.2 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, August 13, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on Wednesday 20th August 2025 (9:05am - 9:35am U.S. Eastern Time). Mr. Steven Lydeamore, Chief Executive O |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 21, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Sunday July 20, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security |
|
| July 21, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 21 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 21 July 2025 Number Issued 32,909,640 The Company gives notice under section 708A(5)(e) of the Corpo |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 18, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday July 18, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security |
|
| July 18, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 18 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 18 July 2025 Number Issued 473,880 The Company gives notice under section 708A(5)(e) of the Corporat |
|
| July 17, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday July 17, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securit |
|
| July 17, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, July 17 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 17 July 2025 Number Issued 877,440 The Company gives notice under section 708A(5)(e) of the Corporat |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 17, 2025 |
FY25 global sales exceed projection, up 49% on prior year Exhibit 99.2 FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global ● Annual sales AUD$7.3 million up 49% on prior year ● June 2025 Quarter AUD$2.0 million up 55% on prior year Australia ● Annual sales AUD$5.2 million up 40% on prior year ● June 2025 Quarter AUD$1.5 million up 58% on prior year North America ● Annual sales AUD$2.0 million up 76% on prior yea |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 4, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Wednesday June 04, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| June 4, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, June 4, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 3 June 2025 Number Issued 116,680 The Company gives notice under section 708A(5)(e) of the Corporati |
|
| May 30, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday May 30, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +security c |
|
| May 30, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, May 30, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 29 May 2025 Number Issued 135,800 The Company gives notice under section 708A(5)(e) of the Corporati |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 30, 2025 |
Exhibit 99.3 May 30, 2025 Letter to Shareholders Highlights: ● Immuron on track to exceed A$7 million in Sales this financial year ● Uniformed Services University anticipates topline results of Travelan® clinical study in October 2025 ● Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025 ● Launch plans underway for ProIBS® in Australia ● Immuron |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 11, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.3 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, April 11, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 10 April 2025 Number Issued 179,664 The Company gives notice under section 708A(5)(e) of the Corpo |
|
| April 11, 2025 |
Exhibit 99.2 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday April 11, 2025 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation IMCAE PERFORMANCE RIGHTS 285, |
|
| April 11, 2025 |
Appendix 2A - Application for quotation of securities Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday April 11, 2025 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities to |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 10, 2025 |
Immuron Travelan® highest sales in history Exhibit 99.1 Immuron Travelan® highest sales in history Sales Highlights (unaudited): Global · Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history · March 2025 Quarter AUD$1.3 million up 2% on prior year · March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia · March 2025 Quarter AUD$0.8 million down 8% on prior year · March 2025 Year to Date AUD$3.7 |
|
| March 7, 2025 |
Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia, March 7, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Coffee Microcaps Conference on Friday 7th March 2025 (11am Australian Eastern time). A copy of the presentation being made is includ |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 5, 2025 |
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) Exhibit 99.1 Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) Melbourne, Australia, March 5, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand in order to launch ProIBS® for the treatme |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| February 28, 2025 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2024 Previous period: For the period ended 31 December 2023 2. Results for announcement to the market $ Revenue from ordinary activities up 69.6 % to 3,994,341 Loss from ordinary activities after tax attributable to the |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 19, 2025 |
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, February 19, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference on Tuesday 18th February 2025 (10.50am U.S. Eastern time). A copy of the presentation being made is included be |
|
| February 19, 2025 |
Exhibit 99.2 EMERGING GROWTH CONFERENCE 18 FEBRUARY 2025 S teven Lydeamore - CEO NASDAQ: IMRN ASX: IMC Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “ intends,” “ plans,” “ believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are inten |
|
| January 17, 2025 |
Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday January 17, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 17, 2025 |
Immuron Travelan® continued strong sales growth Exhibit 99.1 Immuron Travelan® continued strong sales growth Sales Highlights: Global ● December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp ● December 2024 Half Year AUD$4.0 million up 70% on pcp Australia ● December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp ● December 2024 Half Year AUD$2.9 million up 54% on pcp North ● December 2024 Quarter AU |
|
| January 17, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.3 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, January 17, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 15 January 2025 Number Issued 1,801,680 The Company gives notice under section 708A(5)(e) of the |
|
| January 15, 2025 |
Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Exhibit 99.1 Immuron Announces New Research Collaboration targeting Antimicrobial Resistance Highlights: ● New Research Collaboration with Monash University ● One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products ● Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VR |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 15, 2025 |
Exhibit 99.2 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 15/1/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX +security code Security description Maximum Number of +securities to be i |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 14, 2025 |
Immuron Announces Travelan® Clinical Trial Update Exhibit 99.1 Immuron Announces Travelan® Clinical Trial Update Highlights: ● Travelan® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA ● Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results ● Travelan® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses ● Travelan® P2TD (n=866) Uniformed Services University field study |
|
| January 10, 2025 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.2 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, January 10, 2025 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 8 January 2025 Number Issued 2,579,760 The Company gives notice under section 708A(5)(e) of the |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| January 10, 2025 |
Exhibit 99.1 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Friday January 10, 2025 The +securities to be quoted are: +Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B Total number of +securities to be quoted ASX +securi |
|
| January 8, 2025 |
EX-99.1 2 ea022714501ex99-1immuron.htm PROPOSED ISSUE OF SECURITIES - IMC Exhibit 99.1 Appendix 3B - Proposed issue of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement 8/1/2025 The Proposed issue is: A placement or other type of issue Total number of +securities proposed to be issued for a placement or other type of issue ASX |
|
| January 8, 2025 |
6-K 1 ea0227145-6kimmuron.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victo |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity: Immuron Limited ABN: 80 063 114 045 We (the entity) |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.4 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity Immuron Limited ABN 80 063 114 045 We (the entity) gi |
|
| December 10, 2024 |
Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Tuesday December 10, 2024 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be iss |
|
| December 10, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.2 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of Entity: Immuron Limited ABN: 80 063 114 045 We (the entity) |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 22, 2024 |
Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event Melbourne, Australia, November 22, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is includ |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 18, 2024 |
Results of Annual General Meeting Exhibit 99.2 Results of Annual General Meeting Melbourne, Australia, November 18, 2024: Immuron Limited (ASX: IMC, NASDAQ: IMRN) advises that all resolutions considered at the Annual General Meeting held earlier today were carried by a poll. In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, details of the resolutions and the proxies received in respect of each |
|
| November 18, 2024 |
Exhibit 99.1 Immuron 2024 AGM Presentation Highlights: ● Global sales increased 172% in FY24 to $4.90m; Record Travelan® sales of $4.86m ● Record monthly sales in October 2024 of $1.49m ● Completed and reported topline results for Travelan® Phase 2 and NMRC’s Campylobacter clinical trial; planning 2H2025 Phase 3 initiation for Travelan® ● Positive feedback from the FDA to IMM-529 pre-IND filing; p |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| November 14, 2024 |
Appendix 3Y Change of Director’s Interest Notice Exhibit 99.2 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Immuron Limited (ASX: IMC) ABN: 80 063 114 045 We |
|
| November 14, 2024 |
Exhibit 99.1 Appendix 3H - Notification of cessation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday November 14, 2024 Details of +securities that have ceased ASX +security code Security description Number of +securities that have ceased The +securities have ceased due to Date of cessation IMCAD OPTION EXPIRING 13 |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 29, 2024 |
Exhibit 99.1 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name IMMURON LIMITED Date of this announcement Tuesday October 29, 2024 The +securities the subject of this notification are: +Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX Total number of +securities to be issu |
|
| October 18, 2024 |
Exhibit 99.1 IMMURON LIMITED ACN 063 114 045 (ASX code: IMC, NASDAQ code: IMRN) NOTICE OF 2024 ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Date and Time of Meeting: Monday, 18 November 2024 at 11.00 am Place of Meeting: The Offices of K & L Gates, Level 25, Rialto South Tower, 525 Collins Street Melbourne, Victoria And virtually at https://bit.ly/IMCAGM2024 If Shareholders are unable to atte |
|
| October 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 16, 2024 |
Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - addendum Exhibit 99.1 Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - addendum Melbourne, Australia, October 16, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday 16th October 2024 (4.30pm U.S. Eastern time). A |
|
| October 15, 2024 |
Immuron Travelan® continued strong sales growth Exhibit 99.1 Immuron Travelan® continued strong sales growth Sales Highlights: Global ● September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia ● September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America ● September 2024 Quarter AUD$0.5 million up 48% on prior quarter Melbourne, Australia, October 15, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 8, 2024 |
Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Tuesday October 08, 2024 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 8, 2024 |
Notice Under Section 708A(5) of the Corporations Act Exhibit 99.1 Notice Under Section 708A(5) of the Corporations Act Melbourne, Australia, October 8, 2024 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 7 October 2024 Number Issued 1,147,083 The Company gives notice under section 708A(5)(e) of the C |
|
| October 4, 2024 |
NMRC Reports Results for Campylobacter Controlled Human Infection Model Study Exhibit 99.1 NMRC Reports Results for Campylobacter Controlled Human Infection Model Study Melbourne, Australia, October 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) In |
|
| October 1, 2024 |
Exhibit 4.6 Executive employment agreement This executive employment agreement is made on 05 May 2022 between Immuron Limited ACN 063 114 045 of Unit 10, 25-37 Chapman Street, Blackburn North, VIC 3130, Australia (Employer) and Steven Lydeamore (Executive). BACKGROUND A. The Employer has decided to appoint a Chief Executive Officer (CEO) and has further decided to offer the position to the Executi |
|
| October 1, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Lydeamore, Chief Executive Officer of the Company, |
|
| October 1, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2(d) DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Memorandum And Articles of Association Our Constitution Our Constitution is similar in nature to the bylaws of a U. |
|
| October 1, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Steven Lydeamore, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 |
|
| October 1, 2024 |
IMMURON LTD. INCENTIVE-BASED COMPENSATION RECOVERY POLICY Exhibit 97.1 IMMURON LTD. INCENTIVE-BASED COMPENSATION RECOVERY POLICY 1. Policy Purpose. The purpose of this Incentive-Based Compensation Recovery Policy (the “Policy”) is to enable Immuron Ltd. (the “Company”) to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requirements set fort |
|
| October 1, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Immuron Limited (the “Company”) on Form 20-F for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philip Hains, Chief Financial Officer of the Company, cer |
|
| October 1, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER Pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended I, Philip Hains, certify that: 1. I have reviewed this annual report on Form 20-F of Immuron Limited; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements ma |
|
| September 26, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, September 26 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference early on 26 September 2024 (AEST) (25 September 2024, U.S. Eastern Standard Time). A copy of the presentation b |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 9, 2024 |
Attributable to owners of Immuron Limited Exhibit 99.1 Immuron Limited Appendix 4E 30 June 2024 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2024 Name of entity: Immuron Limited ABN: 80 063 114 045 year ended: 30 June 2024 Previous period: 30 June 2023 Results for announcement to the market $ Revenue from ordinary activities Up 171.7% to 4,902,865 Loss from ordinary activities after tax attributable to members U |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) |
|
| September 5, 2024 |
Immuron Plans Phase 2 Trial for IMM-529 following FDA review Exhibit 99.1 Immuron Plans Phase 2 Trial for IMM-529 following FDA review Key Points ● Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) ● Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 ● Investigational new drug (IND) application for IMM-529 pl |
|
| August 21, 2024 |
Immuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Exhibit 99.1 Immuron CEO, Steven Lydeamore presentation at Peak Biotech Showcase Melbourne, Australia, August 21 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Peak Biotech Showcase on Wednesday 21st August 2024 at Work Club Olderfleet, 477 Collins Street, Melbourne, Australia. A copy of the presentation being |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 16, 2024 |
Exhibit 99.1 Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan® Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. Melbourne, Australia, August 16, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 9, 2024 |
Immuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Exhibit 99.1 Immuron CEO, Steven Lydeamore webinar on MarketOpen Direct Connect Melbourne, Australia, August 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be hosting a webinar on MarketOpen Direct Connect on Thursday 8th August 2024, 11:00am AEST (9:00am AWST). This webinar can be viewed live via zoom & you register for FR |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| August 7, 2024 |
Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect Exhibit 99.1 Immuron CEO, Steven Lydeamore to host webinar on MarketOpen Direct Connect Melbourne, Australia, August 7, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on Thursday 8th August 2024, 11:00am AEST (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on addi |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Ind |
|
| July 18, 2024 |
Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Emerging Growth Conference Melbourne, Australia, July 18, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Emerging Growth Conference on July 18th. A copy of the presentat |
|
| July 18, 2024 |
IMMURON LIMITED Level 3, 62 Lygon Street Carlton South, Victoria, 3053, Australia IMMURON LIMITED Level 3, 62 Lygon Street Carlton South, Victoria, 3053, Australia July 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 15, 2024 |
Immuron Travelan® record sales globally, Australia and USA Exhibit 99.1 Immuron Travelan® record sales globally, Australia and USA Sales Highlights: Global ● FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) ● June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia ● FY 2024 AUD$3.7 million up 223% on pcp ● June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA ● FY 2024 Record sales of AUD |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 9, 2024 |
Immuron CEO, Steven Lydeamore to present at Sharewise Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia, July 9, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise on Tuesday 9 July 2024, 11:00am AEST. A copy of the presentation being made is include |
|
| July 8, 2024 |
July 8, 2024 Steven Lydeamore Chief Executive Officer Immuron Limited Level 3, 62 Lygon Street Carlton South, Victoria Australia 3053 Re: Immuron Limited Registration Statement on Form F-3 Filed July 3, 2024 File No. |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 5, 2024 |
Immuron CEO, Steven Lydeamore to present at Sharewise Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Sharewise Melbourne, Australia, July 4, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Sharewise, to be held on Tuesday 9 July 2024, 11:00am AEST. Chief Executive Officer, Steve Lydea |
|
| July 3, 2024 |
Exhibit 107 Calculation of Filing Fee Table F-3 (Form Type) IMMURON LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee C |
|
| July 3, 2024 |
As filed with the Securities and Exchange Commission on July 2, 2024 As filed with the Securities and Exchange Commission on July 2, 2024 Registration No. |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| July 3, 2024 |
AT THE MARKET OFFERING AGREEMENT July 2, 2024 Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT July 2, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: Immuron Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| July 3, 2024 |
AT THE MARKET OFFERING AGREEMENT July 2, 2024 Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 2, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Ladies and Gentlemen: Immuron Limited, a corporation incorporated under the laws of Australia (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used i |
|
| July 2, 2024 |
Exhibit 99.1 IMM-529 pre-IND FDA filing Melbourne, Australia, July 2, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529. CEO, Steven Lydeamore said, “We are excited for ou |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 5, 2024 |
Appendix 3X Initial Director’s Interest Notice Exhibit 99.2 Appendix 3X Initial Director’s Interest Notice Rule 3.19A.1 Appendix 3X Initial Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the followin |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indic |
|
| June 5, 2024 |
Appendix 3Z Final Director’s Interest Notice Exhibit 99.1 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the following in |
|
| May 31, 2024 |
Exhibit 99.2 Board Changes Melbourne, Australia, May 31, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past fe |
|
| May 31, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Peak Sky High Melbourne, Australia, May 31, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1st. A copy of the prese |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 28, 2024 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Revenue from ordinary activities Up 303.6% to 2,355,580 Net loss after tax (from ordinary activities) for the period attributable to members Up (4.8)% to (2,073,182 ) Net |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indica |
|
| May 3, 2024 |
Appendix 3Z Final Director’s Interest Notice Exhibit 99.2 Appendix 3Z Final Director’s Interest Notice Rule 3.19A.3 Appendix 3Z Final Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Immuron Limited ABN 80 063 114 045 We (the entity) give ASX the following in |
|
| May 3, 2024 |
Exhibit 99.1 Board Change Melbourne, Australia, May 3, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non- Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributi |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 23, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at The Watchlist Melbourne, Australia, April 23 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at The Watchlist, to be held on Tuesday 23 rd April 2024 , 12 : 00 pm AEST/ 10 : 00 am A |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| April 15, 2024 |
Immuron to host Live Virtual Event Exhibit 99.1 Immuron to host Live Virtual Event Melbourne, Australia, April 15, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a L |
|
| April 10, 2024 |
Immuron Travelan® sales continued strong growth Exhibit 99.1 Immuron Travelan® sales continued strong growth Sales Highlights: Global ● FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp ● Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia ● FYTD Mar 2024 AUD$2.8 million up 234% on pcp ● Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA ● FYTD Mar 2024 AUD$0.8 million u |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 14, 2024 |
Exhibit 99.1 Immuron CEO, Steven Lydeamore to present at Coffee Microcaps Melbourne, Australia, March 14 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Coffee Microcaps conference in Sydney on March 14 th . A copy of the presentat |
|
| March 14, 2024 |
Notice Under Section 708A (5) of the Corporations Act Exhibit 99.4 Notice Under Section 708A (5) of the Corporations Act Melbourne, Australia, March 14, 2024 This notice is given by Immuron Limited (ASX: IMC; NASDAQ: IMRN) under section 708A(5)(e) of the Corporations Act 2001 (the ‘Corporations Act’). Type Shares Class Ordinary ASX code IMC Date of Issue 12 March 2024 Number Issued 200,000 The Company gives notice under section 708A(5)(e) of the Corp |
|
| March 14, 2024 |
Exhibit 99.3 |
|
| March 14, 2024 |
Total number of +securities on issue Exhibit 99.2 Appendix 2A - Application for quotation of securities Announcement Summary Entity name IMMURON LIMITED Announcement Type New announcement Date of this announcement Thursday March 14, 2024 The +securities to be quoted are: +Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted Total number of +securities |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 7, 2024 |
Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Exhibit 99.1 Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US Highlights: ● Immuron proceeding to Phase 3 registration strategy with the FDA ● Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose ● 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in t |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| March 5, 2024 |
Exhibit 99.1 Market Announcement 5 March 2024 Immuron Limited (ASX: IMC) – Trading Halt Description The securities of Immuron Limited (‘IMC’) will be placed in trading halt at the request of IMC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 7 March 2024 or when the |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indi |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) I |
|
| February 28, 2024 |
Exhibit 99.1 Immuron Limited Appendix 4D Half-year 31 December 2023 Name of entity: Immuron Limited ABN: 80 063 114 045 Half-year ended: 31 December 2023 Previous period: 31 December 2022 Results for announcement to the market $ Revenue from ordinary activities Up 303.6% to 2,355,580 Net loss after tax (from ordinary activities) for the period attributable to members Up (4.8)% to (2,073,182 ) Net |
|
| February 21, 2024 |
Australian Biologics Festival 2024 Exhibit 99.1 Australian Biologics Festival 2024 Melbourne, Australia, February 21, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21st February in Melbourne, Australia. A copy of |
